Action BBIO BRIDGEBIO PHARMA, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues BridgeBio Pharma, Inc.

Actions

BBIO

US10806X1028

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 23/05/2024 		Varia. 5j. Varia. 1 janv.
27,76 USD -5,16 % Graphique intraday de BridgeBio Pharma, Inc. -10,57 % -31,24 %
16/05 Transcript : BridgeBio Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
02/05 Les actions de BridgeBio Pharma baissent après les résultats financiers du premier trimestre MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
BridgeBio Pharma : BBIO BBP 418 – MENA 2024 – Oral Presentation
BridgeBio Pharma : Bank of America Merrill Lynch Healthcare Conference 2024 Presentation
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ESC Heart Failure 2024 – NT-proBNP Insights from the ATTRibute-CM Study
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ESC Heart Failure 2024 – ITT Sensitivity Analysis and Sub-Analysis Comparing Acoramidis and Placebo in Stage 4 CKD in ATTRibute-CM
Certain Restricted Stock Unit Awards of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.
Certain Options of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.
Certain Common Stock of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.
Bridgebio launches bridgebio oncology therapeutics with $200m of private external capital to accelerate the development of its novel precision oncology pipeline
BridgeBio Pharma Shares Decline After Q1 Financial Results
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q1 Revenue $211.1M
BridgeBio Pharma: Q1 Earnings Snapshot
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
BridgeBio Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
BridgeBio Pharma, Inc. announced that it has received $200 million in funding from a group of investors
BridgeBio Pharma : BBIO – BBO-8520 – 2024 AACR – Rapid and Complete Blockade of Effector Binding Results
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BBIO
  4. Actualités BridgeBio Pharma, Inc.
  5. Autres langues
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT